CLL
MCID: CHR418
MIFTS: 51

Chronic Leukemia (CLL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Leukemia

MalaCards integrated aliases for Chronic Leukemia:

Name: Chronic Leukemia 12 55 15 73
Adult Chronic Leukemia 12
Cll 12
Cml 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1036
NCIt 50 C3483
UMLS 73 C1279296

Summaries for Chronic Leukemia

Disease Ontology : 12 A leukemia that develops slowly.

MalaCards based summary : Chronic Leukemia, also known as adult chronic leukemia, is related to chronic myelomonocytic leukemia and leukemia. An important gene associated with Chronic Leukemia is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are Influenza A and Pathways in cancer. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are cellular and hematopoietic system

Wikipedia : 76 Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is... more...

Related Diseases for Chronic Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Chronic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 31.7 TET2 SETBP1 JAK2 CSF3R ASXL1
2 leukemia 31.7 WT1 JAK2 CSF3R BCR
3 leukemia, chronic myeloid 31.0 WT1 STAT5B STAT5A SETBP1 JAK2 CSF3R
4 chronic neutrophilic leukemia 31.0 SRSF2 SETBP1 CSF3R ASXL1
5 juvenile myelomonocytic leukemia 30.9 TET2 STAT5A SETBP1 JAK2
6 myeloid leukemia 29.4 WT1 TET2 JAK2 CSF3R BCR
7 systemic mastocytosis 29.4 TET2 JAK2 ASXL1
8 polycythemia 29.3 TET2 STAT5A JAK2
9 myeloproliferative neoplasm 29.3 TET2 STAT5B JAK2 BCR
10 splenomegaly 29.2 SETBP1 JAK2
11 polycythemia vera 29.1 TET2 STAT5A JAK2
12 myelofibrosis 28.8 TET2 STAT5B STAT5A SRSF2 JAK2 ASXL1
13 myelodysplastic syndrome 28.4 JAK2 CSF3R ASXL1 WT1 TET2 STAT5A
14 leukemia, acute myeloid 27.6 WT1 TET2 STAT5B STAT5A SRSF2 SETBP1
15 cll/sll 12.3
16 hairy cell leukemia 11.4
17 leukemia, chronic lymphocytic 11.3
18 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.1
19 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.1
20 leukemia, t-cell, chronic 11.0
21 subacute leukemia 10.9
22 childhood leukemia 10.9
23 b cell linker protein deficiency 10.2 STAT5B STAT5A
24 b-cell lymphomas 10.2
25 cellular congenital mesoblastic nephroma 10.2 STAT5B STAT5A
26 jak3-deficient severe combined immunodeficiency 10.1 STAT5B STAT5A
27 sm-ahnmd 10.1 TET2 ASXL1
28 anemia, autoimmune hemolytic 10.1
29 diffuse large b-cell lymphoma 10.1
30 hemolytic anemia 10.1
31 prolymphocytic leukemia 10.1
32 neuroblastoma 10.1
33 melioidosis 10.1
34 hepatosplenic t-cell lymphoma 10.1
35 ovarian mucinous neoplasm 10.1 WT1 SRSF2
36 anemia, sideroblastic, and spinocerebellar ataxia 10.1 TET2 RARS
37 pure red-cell aplasia 10.0
38 carney complex, type 1 10.0
39 spondylocarpotarsal synostosis syndrome 10.0
40 caronte 10.0
41 mantle cell lymphoma 10.0
42 t-cell prolymphocytic leukemia 10.0
43 anemia of prematurity 10.0 STAT5B STAT5A
44 subacute myeloid leukemia 10.0 TET2 JAK2
45 lymphoma, hodgkin, classic 9.9
46 gastric cancer 9.9
47 autoimmune lymphoproliferative syndrome, type v 9.9
48 adult t-cell leukemia 9.9
49 pemphigus foliaceus 9.9
50 thrombocytopenia 9.9

Comorbidity relations with Chronic Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Chronic Leukemia:



Diseases related to Chronic Leukemia

Symptoms & Phenotypes for Chronic Leukemia

MGI Mouse Phenotypes related to Chronic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 ABCB4 ASXL1 BCR CSF3R GFI1B JAK2
2 hematopoietic system MP:0005397 10.15 ABCB4 ASXL1 BCR CSF3R GFI1B JAK2
3 endocrine/exocrine gland MP:0005379 10.1 ABCB4 ASXL1 CSF3R JAK2 SOAT1 SRSF2
4 immune system MP:0005387 10.03 ABCB4 ASXL1 BCR CSF3R GFI1B JAK2
5 homeostasis/metabolism MP:0005376 10.02 ABCB4 ASXL1 BCR GFI1B JAK2 SETBP1
6 liver/biliary system MP:0005370 9.81 ABCB4 ASXL1 BCR JAK2 SOAT1 STAT5A
7 mortality/aging MP:0010768 9.7 ASXL1 BCR CSF3R GFI1B JAK2 SETBP1
8 neoplasm MP:0002006 9.1 ABCB4 ASXL1 JAK2 SOAT1 TET2 WT1

Drugs & Therapeutics for Chronic Leukemia

Drugs for Chronic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Not Applicable 220127-57-1 123596
9 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
11
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
13
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
14
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
15
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
16
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1 104987-11-3 445643 439492
17
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
18
Chlorambucil Approved Phase 3 305-03-3 2708
19
alemtuzumab Approved, Investigational Phase 3,Phase 2 216503-57-0
20
Dasatinib Approved, Investigational Phase 3,Phase 1,Phase 2 302962-49-8 3062316
21
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
22 Antimetabolites Phase 2, Phase 3,Phase 1,Not Applicable
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1,Not Applicable
24 Methylprednisolone acetate Phase 2, Phase 3
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
26 Protective Agents Phase 2, Phase 3,Phase 1
27 Autonomic Agents Phase 2, Phase 3
28 Prednisolone acetate Phase 2, Phase 3
29 Calcineurin Inhibitors Phase 2, Phase 3,Phase 1
30 Antiemetics Phase 2, Phase 3
31 Gastrointestinal Agents Phase 2, Phase 3
32 Peripheral Nervous System Agents Phase 2, Phase 3
33 Anti-Inflammatory Agents Phase 2, Phase 3
34 Hormones Phase 2, Phase 3
35 Antilymphocyte Serum Phase 2, Phase 3,Not Applicable
36 Antineoplastic Agents, Hormonal Phase 2, Phase 3
37 Hormone Antagonists Phase 2, Phase 3
38 Neuroprotective Agents Phase 2, Phase 3
39 glucocorticoids Phase 2, Phase 3
40 tyrosine Phase 3,Not Applicable
41
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
42
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
43
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
44
Cytarabine Approved, Investigational Phase 2,Not Applicable 147-94-4 6253
45
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
46
Thiotepa Approved, Investigational Phase 2,Not Applicable 52-24-4 5453
47 Mirabegron Approved Phase 2 223673-61-8
48
Ofatumumab Approved Phase 2 679818-59-8 6918251
49 tannic acid Approved Phase 1, Phase 2,Phase 2
50
Benzocaine Approved, Investigational Phase 1, Phase 2,Phase 2 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
3 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
4 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
5 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
6 Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Completed NCT01511289 Phase 3 Imatinib;Radotinib
7 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
8 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
9 A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Active, not recruiting NCT00471497 Phase 3 nilotinib;imatinib
10 Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Terminated NCT03079505 Phase 3 Dasatinib 100 MG [Sprycel];Nilotinib 150mg oral capsule [Tasigna]
11 Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. Terminated NCT02108951 Phase 3 Nilotinib
12 Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Terminated NCT00519090 Phase 3 Imatinib;Nilotinib (AMN107)
13 Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Unknown status NCT01472055 Phase 2 Fludarabine
14 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) Completed NCT00042016 Phase 2 decitabine (5-aza-2'deoxycytidine)
15 Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Completed NCT00002502 Phase 2 busulfan;cyclophosphamide;cytarabine
16 Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) Completed NCT01218477 Phase 1, Phase 2 Dasatinib;BMS-833923
17 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Completed NCT00378534 Phase 2 Fludarabine;Cyclosporine;Cyclophosphamide
18 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
19 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
20 Stem Cell Transplantation for Patients With Cancers of the Blood Completed NCT00467961 Phase 2
21 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation Completed NCT00859586 Phase 2
22 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed NCT00079391 Phase 2
23 A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00073489 Phase 2 OSI-461
24 Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00230282 Phase 2 Alemtuzumab;Fludarabine;Cytoxan
25 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Completed NCT01336712 Phase 2
26 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT01191190 Phase 2 Ofatumumab/HDMP
27 A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia Completed NCT00431873 Phase 2 MGCD0103
28 A Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy (PONS). Recruiting NCT03807479 Phase 2 Ponatinib
29 Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy Recruiting NCT01521611 Phase 1, Phase 2
30 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
31 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Recruiting NCT01203722 Phase 1, Phase 2 Fludarabine, Cytoxan, TBI, Sirolimus + MMF;Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
32 Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene Recruiting NCT02885766 Phase 1, Phase 2 PF-114
33 Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Active, not recruiting NCT02169791 Phase 2 MLN9708
34 Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Terminated NCT01220297 Phase 2 Sirolimus;Mycophenolate mofetil (MMF);Carmustine;Etoposide;Cyclophosphamide (Cyclo, CY);FTBI
35 Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated NCT00074490 Phase 2 Rituximab;Fludarabine;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Filgrastim
36 Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells Terminated NCT01624701 Phase 1, Phase 2
37 A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) Terminated NCT00076401 Phase 2 Motexafin gadolinium
38 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Completed NCT00077558 Phase 1 fludarabine phosphate;triapine
39 Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer Completed NCT00005785 Phase 1 GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
40 Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Completed NCT00273936 Phase 1 AVN-944 capsules for oral administration
41 Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Recruiting NCT03588936 Phase 1 Nivolumab;Tocilizumab
42 Umbilical Cord Blood Transplantation From Unrelated Donors Recruiting NCT03016806 Phase 1 Cyclophosphamide;Mesna;Busulfan;Fludarabine;Melphalan
43 Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT Not yet recruiting NCT03689894 Phase 1 Ibrutinib;Rituximab
44 A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia Terminated NCT00587457 Phase 1 CAT-8015 5 mcg/kg;CAT-8015 10 mcg/kg;CAT-8015 20 mcg/kg
45 Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias Completed NCT01144793
46 Fungemia in Hematologic Malignancies Completed NCT02451592
47 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985
48 Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia Completed NCT02520895
49 Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor Recruiting NCT02842333 Not Applicable
50 Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes Recruiting NCT02560883

Search NIH Clinical Center for Chronic Leukemia

Genetic Tests for Chronic Leukemia

Anatomical Context for Chronic Leukemia

MalaCards organs/tissues related to Chronic Leukemia:

41
Bone, Bone Marrow, Myeloid, T Cells, B Cells, Lung, Neutrophil

Publications for Chronic Leukemia

Articles related to Chronic Leukemia:

(show top 50) (show all 164)
# Title Authors Year
1
Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia. ( 30509616 )
2018
2
Cancer, Leukemia, Myeloid, Acute (AML, Erythroid Leukemia, Myelodysplasia-Related Leukemia, BCR-ABL Chronic Leukemia) ( 29939652 )
2018
3
Correlation of Cadmium and Magnesium in the Blood and Serum Samples of Smokers and Non-Smokers Chronic Leukemia Patients. ( 27511371 )
2016
4
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. ( 27579615 )
2016
5
Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. ( 27557388 )
2016
6
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country. ( 27123350 )
2016
7
Your patient has chronic leukemia: Now what? ( 27505878 )
2016
8
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. ( 27229716 )
2016
9
Antileukemic Effect of Tualang Honey on Acute and Chronic Leukemia Cell Lines. ( 26613081 )
2015
10
Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report. ( 25985790 )
2015
11
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma. ( 26295844 )
2015
12
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. ( 26107113 )
2015
13
Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome. ( 24811835 )
2014
14
Analysis of the erythroid differentiation effect of flavonoid apigenin on K562 human chronic leukemia cells. ( 25058688 )
2014
15
Chronic leukemia. ( 24267282 )
2013
16
Exaggerated insect bite reaction related to chronic leukemia. ( 23541024 )
2013
17
Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy. ( 23936692 )
2013
18
Incidental diagnosis of a retroperitoneal schwannoma in a patient with chronic leukemia undergoing prostatic biopsy. ( 22760935 )
2012
19
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. ( 22547610 )
2012
20
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 22585692 )
2012
21
Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/I^-catenin function. ( 22708678 )
2012
22
Understanding and Targeting the Wnt/I^-Catenin Signaling Pathway in Chronic Leukemia. ( 23213540 )
2011
23
[Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells]. ( 22333553 )
2011
24
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. ( 21678379 )
2011
25
Prevalence of human herpesvirus 8 DNA in peripheral blood mononuclear cells of acute and chronic leukemia patients in Taiwan. ( 21392127 )
2011
26
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. ( 19633691 )
2010
27
[Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. ( 20352702 )
2010
28
Inhibition of cell growth by Stellera chamaejasme extract is associated with induction of autophagy and differentiation in chronic leukemia K562 cells. ( 20547324 )
2010
29
Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. ( 20376582 )
2010
30
Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia. ( 21049055 )
2010
31
[Treatment of myeloproliferative neoplasms other than chronic leukemia]. ( 19860198 )
2009
32
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. ( 19360458 )
2009
33
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 19812383 )
2009
34
How I treat acute and chronic leukemia in pregnancy. ( 18472198 )
2008
35
Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. ( 17495972 )
2007
36
[Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance]. ( 17956662 )
2007
37
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). ( 17611571 )
2007
38
PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. ( 16914202 )
2007
39
The detection and significance of minimal residual disease in acute and chronic leukemia. ( 17092250 )
2006
40
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). ( 16533723 )
2006
41
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. ( 16019534 )
2005
42
Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. ( 16145067 )
2005
43
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. ( 15998838 )
2005
44
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. ( 15322568 )
2004
45
MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. ( 15126592 )
2004
46
TNR/11q#1 trinucleotide (GCC)n repeat alleles and predisposition to acute and chronic leukemia. ( 15225161 )
2004
47
Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. ( 14551294 )
2003
48
Diagnosis, treatment, and nursing care of patients with chronic leukemia. ( 12830735 )
2003
49
Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic leukemia and solid-organ transplantation. ( 12562340 )
2003
50
Synthesis and induction of apoptosis in B cell chronic leukemia by diosgenyl 2-amino-2-deoxy-beta-D-glucopyranoside hydrochloride and its derivatives. ( 12526837 )
2003

Variations for Chronic Leukemia

Expression for Chronic Leukemia

Search GEO for disease gene expression data for Chronic Leukemia.

Pathways for Chronic Leukemia

Pathways related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 JAK2 SRSF2 STAT5A STAT5B
2 12.61 BCR CSF3R JAK2 STAT5A STAT5B
3 12.38 GFI1B JAK2 STAT5A STAT5B
4
Show member pathways
12.2 CSF3R JAK2 STAT5A STAT5B
5
Show member pathways
12.06 JAK2 STAT5A STAT5B
6 12.02 JAK2 STAT5A STAT5B
7
Show member pathways
12.01 JAK2 STAT5A STAT5B
8
Show member pathways
12 BCR STAT5A STAT5B
9 11.95 JAK2 STAT5A STAT5B
10
Show member pathways
11.91 JAK2 STAT5A STAT5B
11
Show member pathways
11.9 JAK2 STAT5A STAT5B
12
Show member pathways
11.8 JAK2 STAT5A STAT5B
13
Show member pathways
11.79 JAK2 STAT5A STAT5B
14 11.73 JAK2 STAT5A STAT5B
15 11.73 JAK2 STAT5A STAT5B
16
Show member pathways
11.71 JAK2 STAT5A STAT5B
17
Show member pathways
11.65 BCR STAT5A STAT5B
18 11.57 JAK2 STAT5A STAT5B
19 11.47 JAK2 STAT5A STAT5B
20 11.43 JAK2 STAT5A STAT5B
21 11.4 CSF3R JAK2 STAT5A STAT5B
22 11.31 JAK2 STAT5A STAT5B
23 11.25 JAK2 STAT5A STAT5B
24
Show member pathways
11.16 JAK2 STAT5A STAT5B
25 11.13 JAK2 STAT5A STAT5B
26 11.1 JAK2 STAT5A STAT5B
27 11.08 STAT5A STAT5B
28
Show member pathways
11.02 JAK2 STAT5A STAT5B
29
Show member pathways
10.59 JAK2 STAT5A STAT5B
30 10.08 JAK2 STAT5A STAT5B

GO Terms for Chronic Leukemia

Cellular components related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.23 ABCB4 ASXL1 JAK2 RARS SRSF2 STAT5A

Biological processes related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.87 ASXL1 GFI1B JAK2 TET2
2 cytokine-mediated signaling pathway GO:0019221 9.85 CSF3R JAK2 STAT5A STAT5B
3 peptidyl-tyrosine phosphorylation GO:0018108 9.67 BCR JAK2 STAT5A STAT5B
4 platelet-derived growth factor receptor signaling pathway GO:0048008 9.61 BCR JAK2
5 interleukin-7-mediated signaling pathway GO:0038111 9.6 STAT5A STAT5B
6 regulation of multicellular organism growth GO:0040014 9.59 STAT5A STAT5B
7 homeostasis of number of cells GO:0048872 9.58 ASXL1 BCR
8 2-oxoglutarate metabolic process GO:0006103 9.58 STAT5A STAT5B
9 interleukin-15-mediated signaling pathway GO:0035723 9.56 STAT5A STAT5B
10 creatine metabolic process GO:0006600 9.54 STAT5A STAT5B
11 interleukin-2-mediated signaling pathway GO:0038110 9.52 STAT5A STAT5B
12 oxaloacetate metabolic process GO:0006107 9.51 STAT5A STAT5B
13 succinate metabolic process GO:0006105 9.49 STAT5A STAT5B
14 interleukin-9-mediated signaling pathway GO:0038113 9.48 STAT5A STAT5B
15 citrate metabolic process GO:0006101 9.46 STAT5A STAT5B
16 taurine metabolic process GO:0019530 9.43 STAT5A STAT5B
17 valine metabolic process GO:0006573 9.4 STAT5A STAT5B
18 creatinine metabolic process GO:0046449 9.32 STAT5A STAT5B
19 isoleucine metabolic process GO:0006549 9.26 STAT5A STAT5B
20 allantoin metabolic process GO:0000255 9.16 STAT5A STAT5B
21 JAK-STAT cascade GO:0007259 9.13 JAK2 STAT5A STAT5B
22 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.8 JAK2 STAT5A STAT5B

Molecular functions related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.7 ASXL1 GFI1B SETBP1 STAT5A STAT5B TET2
2 protein binding GO:0005515 9.5 ABCB4 ARL11 ASXL1 BCR CSF3R GFI1B
3 protein tyrosine kinase activity GO:0004713 9.26 BCR JAK2 STAT5A STAT5B

Sources for Chronic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....